Next Article in Journal
Bacteriophages with the Ability to Degrade Uropathogenic Escherichia Coli Biofilms
Next Article in Special Issue
Authentication of the R06E Fruit Bat Cell Line
Previous Article in Journal
Interplay between Interferon-Mediated Innate Immunity and Porcine Reproductive and Respiratory Syndrome Virus
Open AccessArticle

Structural Basis for Differential Neutralization of Ebolaviruses

1
Dept. of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
2
Dept. of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
3
Dept. of Medicine, University of California San Diego, La Jolla, CA 92093, USA
4
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD 21702, USA
5
The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
††
Present address: Heptares Therapeutics, Welwyn Garden City, Hertsfordshire, UK AL7 3AX.
Viruses 2012, 4(4), 447-470; https://doi.org/10.3390/v4040447
Received: 1 March 2012 / Revised: 26 March 2012 / Accepted: 27 March 2012 / Published: 5 April 2012
(This article belongs to the Special Issue Advances in Filovirus Research 2012)
There are five antigenically distinct ebolaviruses that cause hemorrhagic fever in humans or non-human primates (Ebola virus, Sudan virus, Reston virus, Taï Forest virus, and Bundibugyo virus). The small handful of antibodies known to neutralize the ebolaviruses bind to the surface glycoprotein termed GP1,2. Curiously, some antibodies against them are known to neutralize in vitro but not protect in vivo, whereas other antibodies are known to protect animal models in vivo, but not neutralize in vitro. A detailed understanding of what constitutes a neutralizing and/or protective antibody response is critical for development of novel therapeutic strategies. Here, we show that paradoxically, a lower affinity antibody with restricted access to its epitope confers better neutralization than a higher affinity antibody against a similar epitope, suggesting that either subtle differences in epitope, or different characteristics of the GP1,2 molecules themselves, confer differential neutralization susceptibility. Here, we also report the crystal structure of trimeric, prefusion GP1,2 from the original 1976 Boniface variant of Sudan virus complexed with 16F6, the first antibody known to neutralize Sudan virus, and compare the structure to that of Sudan virus, variant Gulu. We discuss new structural details of the GP1-GP2 clamp, thermal motion of various regions in GP1,2 across the two viruses visualized, details of differential interaction of the crystallized neutralizing antibodies, and their relevance for virus neutralization. View Full-Text
Keywords: Filovirus; Ebola; ebolavirus; Sudan virus; neutralization: glycoprotein; antibodies; structure Filovirus; Ebola; ebolavirus; Sudan virus; neutralization: glycoprotein; antibodies; structure
Show Figures

MDPI and ACS Style

Bale, S.; Dias, J.M.; Fusco, M.L.; Hashiguchi, T.; Wong, A.C.; Liu, T.; Keuhne, A.I.; Li, S.; Woods, V.L., Jr.; Chandran, K.; Dye, J.M.; Saphire, E.O. Structural Basis for Differential Neutralization of Ebolaviruses. Viruses 2012, 4, 447-470.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop